155 related articles for article (PubMed ID: 36250256)
41. Genetic fusion of P450 BM3 and formate dehydrogenase towards self-sufficient biocatalysts with enhanced activity.
Kokorin A; Parshin PD; Bakkes PJ; Pometun AA; Tishkov VI; Urlacher VB
Sci Rep; 2021 Nov; 11(1):21706. PubMed ID: 34737365
[TBL] [Abstract][Full Text] [Related]
42. A single mutation in cytochrome P450 BM3 induces the conformational rearrangement seen upon substrate binding in the wild-type enzyme.
Joyce MG; Girvan HM; Munro AW; Leys D
J Biol Chem; 2004 May; 279(22):23287-93. PubMed ID: 15020590
[TBL] [Abstract][Full Text] [Related]
43. Flavocytochrome P450 BM3: an update on structure and mechanism of a biotechnologically important enzyme.
Warman AJ; Roitel O; Neeli R; Girvan HM; Seward HE; Murray SA; McLean KJ; Joyce MG; Toogood H; Holt RA; Leys D; Scrutton NS; Munro AW
Biochem Soc Trans; 2005 Aug; 33(Pt 4):747-53. PubMed ID: 16042591
[TBL] [Abstract][Full Text] [Related]
44. Human P450-like oxidation of diverse proton pump inhibitor drugs by 'gatekeeper' mutants of flavocytochrome P450 BM3.
Butler CF; Peet C; McLean KJ; Baynham MT; Blankley RT; Fisher K; Rigby SE; Leys D; Voice MW; Munro AW
Biochem J; 2014 Jun; 460(2):247-59. PubMed ID: 24588219
[TBL] [Abstract][Full Text] [Related]
45. A tailor-made, self-sufficient and recyclable monooxygenase catalyst based on coimmobilized cytochrome P450 BM3 and glucose dehydrogenase.
Valikhani D; Bolivar JM; Dennig A; Nidetzky B
Biotechnol Bioeng; 2018 Oct; 115(10):2416-2425. PubMed ID: 30036448
[TBL] [Abstract][Full Text] [Related]
46. Identification of mutant Asp251Gly/Gln307His of cytochrome P450 BM3 for the generation of metabolites of diclofenac, ibuprofen and tolbutamide.
Tsotsou GE; Sideri A; Goyal A; Di Nardo G; Gilardi G
Chemistry; 2012 Mar; 18(12):3582-8. PubMed ID: 22337118
[TBL] [Abstract][Full Text] [Related]
47. Characterization of the structure and interactions of P450 BM3 using hybrid mass spectrometry approaches.
Jeffreys LN; Pacholarz KJ; Johannissen LO; Girvan HM; Barran PE; Voice MW; Munro AW
J Biol Chem; 2020 May; 295(22):7595-7607. PubMed ID: 32303637
[TBL] [Abstract][Full Text] [Related]
48. Phenylalanine 393 exerts thermodynamic control over the heme of flavocytochrome P450 BM3.
Ost TW; Miles CS; Munro AW; Murdoch J; Reid GA; Chapman SK
Biochemistry; 2001 Nov; 40(45):13421-9. PubMed ID: 11695888
[TBL] [Abstract][Full Text] [Related]
49. Molecular Determinants of Substrate Affinity and Enzyme Activity of a Cytochrome P450
Geronimo I; Denning CA; Heidary DK; Glazer EC; Payne CM
Biophys J; 2018 Oct; 115(7):1251-1263. PubMed ID: 30224054
[TBL] [Abstract][Full Text] [Related]
50. Cobaltocene-mediated catalytic monooxygenation using holo and heme domain cytochrome P450 BM3.
Udit AK; Arnold FH; Gray HB
J Inorg Biochem; 2004 Sep; 98(9):1547-50. PubMed ID: 15337607
[TBL] [Abstract][Full Text] [Related]
51. Expanding the applicability of cytochrome P450s and other haemoproteins.
Ariyasu S; Stanfield JK; Aiba Y; Shoji O
Curr Opin Chem Biol; 2020 Dec; 59():155-163. PubMed ID: 32781431
[TBL] [Abstract][Full Text] [Related]
52. A single mutation in cytochrome P450 BM3 changes substrate orientation in a catalytic intermediate and the regiospecificity of hydroxylation.
Oliver CF; Modi S; Sutcliffe MJ; Primrose WU; Lian LY; Roberts GC
Biochemistry; 1997 Feb; 36(7):1567-72. PubMed ID: 9048540
[TBL] [Abstract][Full Text] [Related]
53. Flavin supported fatty acid oxidation by the heme domain of Bacillus megaterium cytochrome P450BM-3.
Gonvindaraj S; Li H; Poulos TL
Biochem Biophys Res Commun; 1994 Sep; 203(3):1745-9. PubMed ID: 7945324
[TBL] [Abstract][Full Text] [Related]
54. Rational re-design of the substrate binding site of flavocytochrome P450 BM3.
Ost TW; Miles CS; Murdoch J; Cheung Y; Reid GA; Chapman SK; Munro AW
FEBS Lett; 2000 Dec; 486(2):173-7. PubMed ID: 11113461
[TBL] [Abstract][Full Text] [Related]
55. Effect of replacement of ferriprotoporphyrin IX in the haem domain of cytochrome P-450 BM-3 on substrate binding and catalytic activity.
Modi S; Primrose WU; Lian LY; Roberts GC
Biochem J; 1995 Sep; 310 ( Pt 3)(Pt 3):939-43. PubMed ID: 7575430
[TBL] [Abstract][Full Text] [Related]
56. The dimeric form of flavocytochrome P450 BM3 is catalytically functional as a fatty acid hydroxylase.
Neeli R; Girvan HM; Lawrence A; Warren MJ; Leys D; Scrutton NS; Munro AW
FEBS Lett; 2005 Oct; 579(25):5582-8. PubMed ID: 16214136
[TBL] [Abstract][Full Text] [Related]
57. Critical residues involved in FMN binding and catalytic activity in cytochrome P450BM-3.
Klein ML; Fulco AJ
J Biol Chem; 1993 Apr; 268(10):7553-61. PubMed ID: 8463285
[TBL] [Abstract][Full Text] [Related]
58. Screening of a minimal enriched P450 BM3 mutant library for hydroxylation of cyclic and acyclic alkanes.
Weber E; Seifert A; Antonovici M; Geinitz C; Pleiss J; Urlacher VB
Chem Commun (Camb); 2011 Jan; 47(3):944-6. PubMed ID: 21079837
[TBL] [Abstract][Full Text] [Related]
59. Kinetics and activation parameters for oxidations of styrene by Compounds I from the cytochrome P450(BM-3) (CYP102A1) heme domain and from CYP119.
Yuan X; Wang Q; Horner JH; Sheng X; Newcomb M
Biochemistry; 2009 Sep; 48(38):9140-6. PubMed ID: 19708688
[TBL] [Abstract][Full Text] [Related]
60. Control of the stereo-selectivity of styrene epoxidation by cytochrome P450 BM3 using structure-based mutagenesis.
Huang WC; Cullis PM; Raven EL; Roberts GC
Metallomics; 2011 Apr; 3(4):410-6. PubMed ID: 21240430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
